Robert Sangrigoli, MD
Clinical Cardiac Electrophysiology · Doylestown, PANPI 1619976768
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 87.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $8,630 and has fallen 91.9% since, to $697 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in PA, where the typical reported total is $15,643.
Across 117 payments — averaging $122.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$13K
- Abbott$709
- Novartis$250
- E.r. Squibb & Sons, L.L.C.$209
- Boston Scientific$202
- Pfizer$86
- plus $367 from 12 others
Across 106 payments — averaging $3169.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$245K
- Abbott$82K
- Amarin Pharma, Inc.$9K
What the payments were for
- Consulting fees$1,0507%
- Speaking & faculty fees$8,10056%
- Travel & lodging$2,92720%
- Food & beverage$2,27316%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 38 | $12,541 |
| Abbott | 18 | $709 |
| Novartis | 13 | $250 |
| E.r. Squibb & Sons, L.L.C. | 14 | $209 |
| Boston Scientific | 9 | $202 |
| Pfizer | 6 | $86 |
| AstraZeneca | 4 | $59 |
| Actelion Pharmaceuticals US, Inc. | 2 | $54 |
| Johnson & Johnson | 3 | $48 |
| Biosense Webster, Inc. | 2 | $47 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Philips North America LLC | 1 | $23 |
| Boehringer Ingelheim | 1 | $20 |
| Merck | 1 | $17 |
| Cardiva Medical, Inc. | 1 | $17 |
| Amgen | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arctic Front$8,100
- PulseSelect$1,755
- AVEIR$243
- COBALT DR MRI SURESCAN$149
- AURORA EV-ICD MRI SURESCAN$102
- AZURE XT DR MRI SURESCAN$101
How this compares
$14,363 in reported general payments places this provider in the 45th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
See all clinical cardiac electrophysiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 379 | $486,069 |
| XareltoRivaroxaban | 182 | $210,033 |
| Repatha SureclickEvolocumab | 14 | $15,914 |
| FarxigaDapagliflozin Propanediol | 17 | $13,749 |
| Dofetilide | 19 | $8,732 |
| Metoprolol Succinate | 403 | $7,799 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 20 | $6,180 |
| Amiodarone Hcl | 84 | $3,515 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 36 | $2,486 |
| Atorvastatin Calcium | 175 | $2,346 |
| SotalolSotalol Hcl | 64 | $1,795 |
| Midodrine Hcl | 29 | $1,692 |
| Lisinopril | 164 | $1,691 |
| Propafenone Hcl | 32 | $1,582 |
| Valsartan | 34 | $1,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $86 | $486,069379 claims |
| Johnson & JohnsonXarelto | $48 | $210,033182 claims |
| AstraZenecaFarxiga | $59 | $13,74917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
Other clinical cardiac electrophysiology in Doylestown
- Philip WienerDoylestown$63K
- Seth WorleyLancaster$3.7M
- John ChenaridesPittsburgh$750K
- Fermin GarciaPhiladelphia$684K
- Ralph VerdinoPhiladelphia$682K
- Pugazhendhi VijayaramanWilkes Barre$594K
- Pasquale SantangeliPhiladelphia$581K
- Joshua SilversteinPittsburgh$557K
- Francis MarchlinskiPhiladelphia$469K
- Joshua CooperPhiladelphia$405K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.